News headlines about CASI Pharmaceuticals (NASDAQ:CASI) have been trending somewhat positive recently, according to Accern Sentiment Analysis. Accern scores the sentiment of news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. CASI Pharmaceuticals earned a news sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 44.9350949226885 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern’s rankings:
- CytRx (CYTR) and CASI Pharmaceuticals (CASI) Financial Survey (americanbankingnews.com)
- EPS Calculations to Consider – CASI Pharmaceuticals Inc (NASDAQ: CASI) (stocksmarketcap.com)
- Stock’s Technical Analysis – CASI Pharmaceuticals Inc (NASDAQ: CASI) (stockspen.com)
- CASI Pharmaceuticals, Inc. (CASI) exchanged 5168698 shares unusually on 21 June 2018 (nasdaqchronicle.com)
- Benefits to hold these: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Hess Corporation (NYSE:HES), Texas Capital … (thestreetpoint.com)
Several analysts have commented on CASI shares. ValuEngine downgraded CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. BidaskClub downgraded CASI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, June 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of CASI Pharmaceuticals in a research note on Wednesday, April 4th.
CASI Pharmaceuticals (NASDAQ:CASI) last released its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.02. equities research analysts expect that CASI Pharmaceuticals will post -0.22 earnings per share for the current year.
CASI Pharmaceuticals Company Profile
CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops therapeutics addressing cancer and other unmet medical needs in China. Its lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma and triple-negative breast cancer.
Receive News & Ratings for CASI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.